文献速递药物相互作用治疗药物监测与药物基因组学抗栓抗凝管理

华法林-利福平-基因相互作用:回顾性遗传病例对照研究

Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case-Control Study.
PubMed 文献 · Clin Pharmacol Ther · 2023-03-09

研究纳入2016至2022年卡塔尔36例华法林与利福平联用患者(22例应答者、14例无应答者),检测CYP2C9、VKORC1和CYP4F2基因型。应答者携带一个以上华法林增敏CYP2C9/VKORC1等位基因的比值比为23.2(95%CI 3.2-195.6,P=0.0001),提示遗传变异可解释联用时华法林反应差异。

要点

  • 联用利福平时,携带华法林增敏CYP2C9/VKORC1等位基因者更易出现华法林应答。
  • 基因预测的相互作用前华法林剂量越低,华法林敏感指数越高(r=-0.58)。
  • 增敏基因携带者的治疗范围时间百分比和华法林敏感指数均显著高于非携带者。

核心结论

  • 华法林增敏CYP2C9/VKORC1基因型及较低的基因预测华法林剂量,与联用利福平患者更高的华法林敏感性和更佳抗凝质量相关。

研究设计与样本

  • 回顾性、遗传、病例对照研究,纳入2016至2022年卡塔尔多哈Hamad Medical Corporation的36例华法林与利福平联用患者,其中应答者22例、无应答者14例。

主要发现

  • 应答者携带一个以上华法林增敏CYP2C9/VKORC1等位基因的可能性显著高于无应答者(OR=23.2,95%CI 3.2-195.6;P=0.0001)。
  • 应答者的平均基因预测相互作用前剂量显著低于无应答者(P<0.001),且与华法林敏感指数呈负相关(r=-0.58;P=0.0002)。
  • 增敏CYP2C9/VKORC1等位基因携带者的治疗范围时间百分比中位数和平均华法林敏感指数均显著高于非携带者(P=0.017和P=0.0004)。
  • 增敏CYP2C9/VKORC1基因型与联用利福平时较低的华法林剂量需求相关,而非携带者需超过上述剂量两倍以上才能应答。

临床怎么用

  • 对联用利福平的患者,可考虑检测CYP2C9和VKORC1基因型以辅助预判华法林应答及剂量需求。

局限性

  • 研究为回顾性设计,样本量较小(共36例,应答者22例、无应答者14例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase should overcome this interaction, most reported cases over the last 50 years have not responded even to high warfarin doses, but some have responded to modest doses. To investigate the genetic polymorphisms' impact on this unexplained interpatient variability, we performed genotyping of CYP2C9, VKORC1, and CYP4F2 for warfarin and rifampin concomitant receivers from 2016 to 2022 at Hamad Medical Corporation, Doha, Qatar. We identified and included 36 patients: 22 responders and 14 nonresponders. Warfarin-responders were significantly more likely to have one or more warfarin-sensitizing CYP2C9/VKORC1 alleles than nonresponders (odds ratio = 23.2, 95% confidence interval = 3.2-195.6; P = 0.0001). The mean genetic-based pre-interaction calculated dose was significantly lower for responders than for nonresponders (P < 0.001); and was negatively correlated with warfarin sensitivity index (WSI) (r = -0.58; P = 0.0002). The median percentage time in therapeutic range and mean WSI were significantly higher in the warfarin-sensitizing CYP2C9/VKORC1 alleles carriers than noncarriers (P = 0.017 and 0.0004, respectively). Whereas the warfarin-sensitizing CYP2C9/VKORC1 genotypes were associated with modest on-rifampin warfarin dose requirements, the noncarriers would have required more than double these doses to respond. Warfarin-sensitizing CYP2C9/VKORC1 genotypes and low genetic-based warfarin calculated doses were associated with higher warfarin sensitivity and better anticoagulation quality in patients receiving rifampin concomitantly.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Salem M, El-Bardissy A, Elshafei MN, et al. Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case-Control Study. Clin Pharmacol Ther. 2023. PMID: 36789833. doi:10.1002/cpt.2871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。